吡咯替尼联合曲妥珠单抗、白蛋白结合型紫杉醇治疗Her-2阳性晚期乳腺癌的疗效分析

Efficacy of pyrotinib combined with trastuzumab and albumin-bound paclitaxel for HER2-positive advanced breast cancer

摘要:

目的 分析吡咯替尼（Py）联合曲妥珠单抗、白蛋白结合型紫杉醇对人类表皮生长因子受体-2（Her-2）阳性晚期乳腺癌的治疗效果。方法 选取2019年1月-2024年1月中国人民解放军联勤保障部队第九〇四医院（无锡市太湖医院）收治的82例Her-2阳性晚期乳腺癌患者，按照不同治疗方法分为对照组和观察组。40例对照组采取曲妥珠单抗、白蛋白结合型紫杉醇治疗，42例观察组在对照组基础上加用Py治疗，比较两组治疗效果。结果 观察组客观缓解率和疾病控制率均高于对照组（P <0.05）。观察组治疗前后血清癌胚抗原、糖类抗原125、糖类抗原153、CD4⁺、CD8⁺、CD4⁺/CD8⁺、卡氏功能状态评分和乳腺癌患者生命质量测定量表评分的差值均大于对照组（P <0.05）。两组不良反应总发生率比较，差异无统计学意义（P >0.05）。观察组生存曲线优于对照组（P <0.05）。结论 Py联合曲妥珠单抗、白蛋白结合型紫杉醇治疗Her-2阳性晚期乳腺癌患者，可降低肿瘤标志物水平，增强机体抗肿瘤能力，提高患者生活质量和生存率，且未显著增加不良反应发生率，显示出良好的近期疗效与安全性。

Abstract:

Objective To analyze the effect of pyrotinib (Py) combined with trastuzumab and albumin-bound paclitaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer.Methods A total of 82 patients with HER2-positive advanced breast cancer admitted to our hospital between January 2019 and January 2024 were selected, and divided into two groups according to different treatment regimens. The control group (n = 40) received trastuzumab plus albumin-bound paclitaxel, while the observation group (n = 42) received additional Py therapy. The therapeutic effect of the two groups was compared.Results The objective response rate and disease control rate in the observation group were significantly higher than those in the control group (P < 0.05). The differences in serum levels of carcinoembryonic antigen, carbohydrate antigen 125, and carbohydrate antigen 153, CD4⁺ and CD8⁺ levels, CD4⁺/CD8⁺ ratio, Karnofsky Performance Status, and quality of life scale scores before and after treatment were significantly greater in the observation group than in the control group (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05). The survival curve of the observation group was significantly better than that of the control group (P < 0.05).Conclusion The addition of pyrotinib to trastuzumab and albumin-bound paclitaxel in the treatment of HER2-positive advanced breast cancer effectively reduces the levels of tumor markers, enhances anti-tumor immunity, and improves quality of life and survival rates, without significantly increasing adverse reactions, demonstrating favorable short-term efficacy and safety.